Immunotherapy in the treatment of lymphoma.

Autor:	Popovic LS; Department for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia. lazar.popovic@mf.uns.ac.rs., Matovina-Brko G; Department for Medical Oncology, Oncology Institute of Vojvodina, Novi Sad 21000, Serbia., Popovic M; Department for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia., Popovic M; Department for Nephrology and Clinical Immunology, Clinical Center of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia., Cvetanovic A; Department for Medical Oncology, Clinical Center of Nis, University of Nis, Nis 18000, Serbia., Nikolic I; Department for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia., Kukic B; Department for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia., Petrovic D; Department for Medical Oncology, Oncology Institute of Vojvodina, Novi Sad 21000, Serbia.
Jazyk:	angličtina
Zdroj:	World journal of stem cells [World J Stem Cells] 2021 Jun 26; Vol. 13 (6), pp. 503-520.
DOI:	10.4252/wjsc.v13.i6.503
Abstrakt:	Relapsed or refractory non-Hodgkin's lymphomas, especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat diseases. Patients who do not respond to initial therapy or experience relapse are treated with salvage regimens, and if eligible for aggressive therapy, treatment is continued with high-dose chemotherapy and autologous stem cell transplantation. Current therapy options can cure substantial numbers of patients, however for some it is still an uncurable disease. Numerous new drugs and cell therapies are being investigated for the treatment of relapsed or refractory lymphomas. Different types of immunotherapy options have shown promising results, and some have already become the standard of care. Here, we review immunotherapy options for the treatment of lymphoma and discuss the results, positions, practical aspects, and future directions of different drugs and cellular therapies for the treatment of this disease. Competing Interests: Conflict-of-interest statement: The authors have no competing interests to declare. (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu